A Prospective Comparative Study Of Outcomes With Proton And Photon Radiation In Prostate Cancer (COMPPARE)

Two types of radiation treatment are routinely used for prostate cancer: photon (X-ray) therapy and proton therapy. The purpose of this study is to directly compare the two therapies to determine which one has better disease control and fewer patient-reported and physician-reported side effects.

Inova Schar Cancer Institute
8081 Innovation Park Dr.
Fairfax, VA 22031

A department of Inova Fairfax Hospital

• Adult males between 30 and 85 years of age
• A life expectancy estimation (LEE) of ≥ 8 years
• Diagnosis of adenocarcinoma of the prostate
• Localized prostate cancer, as confirmed by staging with PSA, biopsy, Gleason score, DRE with or without mpMRI, and clinical stage
• Additional eligibility information in protocol

• Findings of metastatic disease (nodal or distant, N1 or M1)
• Prior procedures for treatment of prostate cancer, such as radical or robotic prostatectomy, high-intensity focused ultrasound, cryosurgery, or focal prostatectomy [note that procedures used for benign prostatic hyperplasia symptoms, such as transurethral resection of the prostate (TURP) and GreenLight Laser Therapy, are acceptable]
• Previous prostate cancer treatment with the exception of ADT according to NCCN guidelines
• History of invasive rectal malignancy or other pelvic malignancy, regardless of disease-free interval
• Active inflammatory bowel disease (i.e., patients requiring medical interventions or who are symptomatic)
• Prior pelvic RT for any reason
• Additional ineligibility in protocol

Additional information can be found at: https://clinicaltrials.gov/ct2/show/NCT03561220